STOCKHOLM, Dec. 19, 2019 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that 198 out of a total of 200 patients required for Part A of the Company’s pivotal Phase 3 study NefIgArd, have been randomized. Top line...
BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that, following a strategic...
Demonstrated 44% improvement over baseline of visible (non-vellus) hair count, a well-established hair growth measure (p value < 0.001) Study met primary endpoint and identified optimal frequency and number of treatments with Follica’s proprietary device in...
Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Disease First-in-human safety and tolerability Phase 2 clinical trial ‘Danube’ in 36 patients met primary objective of selecting the dose of NCX 4251 for...
VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce the...
– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage...
Email
Text